Teva Pharmaceutical Industries Limited (NYSE:TEVA) has tumbled 1.89% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.13% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.71%. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has underperformed the index by 0.78% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $52.03 on Friday but the bulls could not build on the opening and the stock topped out at $52.50 for the day. The stock traded down to $51.60 during the day, due to lack of any buying support eventually closed down at $52.01 with a loss of -0.38% for the day. The stock had closed at $52.21 on the previous day. The total traded volume was 3,758,816 shares.
The company shares have dropped -13.32% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $72.31 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $52.57 and the 200 Day Moving Average price is recorded at $57.79.
Many analysts have stated their opinion on the company shares. Credit Suisse initiates coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $60 per share. The rating by the firm was issued on May 4, 2016. Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.03% of Teva Pharmaceutical Industries Limited shares.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.